Menu
Home
TMU
FAQ
Sitemap
正體中文
News
Announcements
Events
Business
FAQ
FAQ: IRB
FAQ: Clinical Trial
FAQ: Biobank
Charges
Public Area
About OHR
OHR Overview
Dean
OHR Members
Department
JIRB Administration Section
Data Safety Managing Section
Joint Clinical Research Center
Joint Biobank
Business
Clinical Trial
Clinical Trial Agreement
Investigator-Initiated Trial
Project Writing Consultation
Ongoing Clinical Trials
Biobank
Biobank Application
Charges
TMU-JIRB
About TMU-JIRB
Introduction
Members
SOP
Application System
TMU-eJIRB System
IRB Account Controller Application
Application Process
Charges
Meeting Date
FAQs
Download
Forms
Clinical Trial
Regulation
TMU Regulation
Domestic Regulation
Related Regulation
Links
Online Portals
TMU Online Resources
External Online Resources
Affiliated Hospitals
REACTA 2024
Contact
Contact Info
Website Feedback Form
Home
Ongoing Clinical Trials
Ongoing Clinical Trials
Indication
All
overweight and obesity
Esophagus:process
Knee Osteoarthritis (KOA)
Pancreatic Cancer
Dermatosis/skin disease
Cell Therapy
Asthma
Solid tumors
Chronic obstructive pulmonary disease (COPD)
Rhinosinusitis
Lung Cancer
Endometriosis
Diabetes
Hepatitis B or D Infection
Hepatocellular Carcinoma (HCC)
Pregnant Women
Non-Alcoholic Fatty Liver
Healthy Volunteer
Systemic Lupus Erythematosus
Sjögren’s syndrome (NEPTUNUS-2)
Gout
COVID-20
Hemodialysis
Chronic Kidney Disease
Chronic Kidney Disease
heart failure
major adverse cardiovascular events
Coronary Syndrome
Spinal Cord Injuries (SCI)
High Blood Pressure/Hypertension
Hypercholesterolemia
Urinary Tract Infections
Influenza Vaccine
COVID-21
Breast Cancer
Cancer Patients
Interstitial lung disease
Femtosecond Ophthalmic
Chronic Kidney Disease (CKD)
Melanoma
Tibial fracture
COVID-19
Acute Respiratory Syncytial Virus Infection
Viral Lung Infection Requiring Supplemental Oxygen (TILIA)
Focal segmental glomerulosclerosis (FSGS)
Nephropathy
Diabetes and Chronic Kidney Disease
chronic obstructive pulmonary disease (COPD)
Chronic Plaque Psoriasis
Atopic Dermatitis
Myasthenia Gravis
Proliferative Lupus Nephritis
Knee Osteoarthritis (KOA)
Ulcerative Colitis (UC)
Atrial fibrillation
Ischemic stroke
Persistent Cancer Pain
Institution
All
TMUH
WFH
SHH
Department
All
Colorectal Surgery
Oral Surgery
Orthopedics
Radiation Oncology
Dermatology
Plastic Surgery
Pulmonary Medicine/Sleep Clinic
Pulmonary Medicine
Obstetrics
Endocrinology and Metabolism
Gastroenterology
Pediatrics
Rheumatology
Family Medicine
Nephrology
Cardiology
Urology
Hematology and Oncology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Internal Medicine/Neurology
Hematology And Oncology
Cardiovascular Surgery
Infection
Neurology
Allergy, Immunology and Rheumatology
Principal Investigator
All
Wei Wang
Chia-Yu Wu
Jia-Lin, Wu
Long-Sheng Lu
Lee,Tsung-Ju
Li-Wei Tang
Pai-Chien Chou
Chao-Hua Chiu
Timothy Chiu
Shuen-Fu Weng
Wei-Yu Kao
Heng-Kien Au
Chun-Chao Chang
Chia-Yau Chang
Chi-Ching Chang
Shy-Shin Chang
Cheng Tiong
Han-Pin Kuo
Hsi-Hsien, Chen
Chun-Yao Huang
MING-CHE LIU
Yen-Lin Liu
Jia-Ruey Tsai
Yung-Hsiao,Chiang
Shih-Hsin Hsiao
Chi-Li Chung
Le-Ming Wang
Chien-Liang Wu
Jia-Ying Sung
Tzeon-Jye Chiou
Chun-Che Shih
Chia-Lun Chang
Kuo Yi-Jie
Fu-Lun Chen
Tsong-Yih Ou
Ming-Hsiung Hsieh
Mai-Szu Wu
Kang-Yun Lee
Woan-Ruoh Lee
Hou-Chang Chiu
Yu-Sheng Chang
Yung-Ho Hsu
Chih-Hwa Chen
Ming-Yao Chen
Chen Kuan-Yuan
Tzu-Tao Chen
Lung Chan
Po-Hao Feng
Chia-Lun Chou
Tsu-Yi Chao
Wei-Hong Cheng
Yao-Yu Hsieh
Protocol Title
Search
Clear
TMU-JIRB No.
Protocol Title
Indication
Institution
Department
Principal Investigator
Contact
N202104119
SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor – A ctDNA Guided Early Switch Study
Breast Cancer
TMUH
Hematology and Oncology
Jia-Ruey Tsai
Yin-Ju Chen
02-27372181 #7606
N202111011
A Randomized Controlled Phase II, Two-Arm Study of Umbilical Cord Blood Cell Trans-plant (MC001) into Injured Spinal Cord followed by the Locomotor Training for Patients with Chronic Spinal Cord Injuries (SCI).
Spinal Cord Injuries (SCI)
TMUH
Neurosurgery
Yung-Hsiao,Chiang
Wei-Ling Lan
0970405675
N202203154
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Solid tumors
TMUH
Pulmonary Medicine
Shih-Hsin Hsiao
Pei-Rong Luo
0911135352
N202207026
A Prospective Observational Human Subject Research to Explore the HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan
Cancer Patients
TMUH
Pulmonary Medicine
Shih-Hsin Hsiao
Yi-Ann Chen
02-27372181 #7633
N202011053
Non-Interventional Collecting Evidences For ILD in Taiwan:Optimized Novel Therapy
Interstitial lung disease
TMUH
Pulmonary Medicine
Chi-Li Chung
Yin-Ju Chen
02-27372181 #7607
N202108058
Develop the umbilical cord mesenchymal stem cell model from human umbilical cord
Cell Therapy
WFH
Obstetrics/Gynecology
Le-Ming Wang
Yi-Jie Ding
02-89797888 #118
N202005019
Intracorneal Lenticular Extraction refractive surgery with Femtosecond Ophthalmic laser Femton F1
Femtosecond Ophthalmic
WFH
Ophthalmology
Chien-Liang Wu
Hsiu-Yen Wang
0229307930 #2543
N202005020
Femtosecond FLEX Application with Ophthalmic Femton F1
Femtosecond Ophthalmic
WFH
Ophthalmology
Chien-Liang Wu
Hsiu-Yen Wang
0229307930 #2544
N202206025
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Kidney Disease (CKD)
WFH
Internal Medicine/Neurology
Jia-Ying Sung
Hsiu-Chen Chang
0229307930 #2550
N202208004
A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
WFH
Hematology And Oncology
Tzeon-Jye Chiou
Sih-Chen Wang
0958131385
1
2
3
4
5
6
7
8
9
10
11
12
13
/
13
TOP